|
US 11,931,463 B2 |
|
| All-in-one fixed-dose combination for treating Helicobacter pylori infection |
| Reza Fathi, Oradell, NJ (US); Gilead Raday, Palo Alto, CA (US); Guy Goldberg, Tel Aviv (IL); and Patrick Gosselin, Laval (CA) |
| Assigned to RedHill Biopharma Ltd., Tel-Aviv (IL) |
| Filed by RedHill Biopharma Ltd., Tel-Aviv (IL) |
| Filed on Aug. 20, 2021, as Appl. No. 17/408,111. |
| Application 17/408,111 is a continuation of application No. 16/515,621, filed on Jul. 18, 2019, granted, now 11,135,172. |
| Application 16/515,621 is a continuation of application No. 16/274,634, filed on Feb. 13, 2019, granted, now 10,898,439, issued on Jan. 26, 2021. |
| Application 16/274,634 is a continuation of application No. 15/466,305, filed on Mar. 22, 2017, granted, now 10,238,606, issued on Mar. 26, 2019. |
| Application 15/466,305 is a continuation of application No. 15/135,309, filed on Apr. 21, 2016, granted, now 9,603,806, issued on Mar. 28, 2017. |
| Application 15/135,309 is a continuation of application No. 14/522,921, filed on Oct. 24, 2014, granted, now 9,498,445, issued on Nov. 22, 2016. |
| Application 14/522,921 is a continuation of application No. 14/179,197, filed on Feb. 12, 2014, granted, now 9,050,263, issued on Jun. 9, 2015. |
| Claims priority of provisional application 61/764,401, filed on Feb. 13, 2013. |
| Claims priority of provisional application 61/764,385, filed on Feb. 13, 2013. |
| Prior Publication US 2022/0062188 A1, Mar. 3, 2022 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. A61K 9/48 (2006.01); A61K 9/50 (2006.01); A61K 31/395 (2006.01); A61K 31/43 (2006.01); A61K 31/435 (2006.01); A61K 31/438 (2006.01); A61K 31/4439 (2006.01) |